Full Press Release Details
Chairman and Chief Executive Officer
Director of Strategic Marketing
The Event Group, Incorporated
ELECTROMED, INC. TO LIST ON THE NYSE AMEX
New Prague, Minnesota - September 22, 2011 -
Electromed, Inc. (NASDAQ: ELMD) today announced that its Board of Directors has voted to transfer its stock exchange listing from
the NASDAQ Capital Market to the NYSE Amex. Electromed currently expects that its common stock will commence trading on the NYSE
Amex on October 3, 2011 and will continue to be listed under the ticker symbol "ELMD." Until it begins trading on the
NYSE Amex, Electromed's common stock will continue to trade on the NASDAQ Capital Market.
Robert Hansen, Chairman and CEO, commented on the transfer, saying,
"After careful consideration of our capital market alternatives, our Board of Directors determined it would be appropriate
to transfer our listing to the NYSE Amex. We believe this decision will afford added visibility to our investors and reflects our
effort to provide our current and future shareholders with an efficient market for trading Electromed shares."
"We welcome Electromed, Inc. to the NYSE Euronext family of
listed companies and to NYSE Amex," said Scott Cutler, Co-Head of U.S. Listings and Cash Execution, NYSE Euronext. "Electromed
and its shareholders will benefit from superior market quality and technology, a broad array of issuer and investor services, and
a global brand association. We look forward to building a strong and lasting partnership with the Company and its shareholders."
About Electromed, Inc.
Electromed, Inc., founded in 1992 and headquartered in New Prague,
Minnesota, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest
Airway Clearance System and related products, to patients with compromised pulmonary function. Further information about the Company
can be found at www.Electromed.com.
Cautionary Statements
Certain statements found in this
release may constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect the speaker's current views with respect to future events and financial performance and include any statement
that does not directly relate to a current or historical fact. The forward-looking statements in this release include those relating
to the expected date that trading will commence on the NYSE Amex and benefits that will result from listing on the NYSE Amex. Forward-looking
statements cannot be guaranteed and actual results may vary materially due to the uncertainties and risks, known and unknown, associated
with such statements. Examples of risks and uncertainties for Electromed include, but are not limited to, delays in the review
of our listing application with the NYSE Amex, the impact of market fluctuations on trading activity for Electromed common stock
and factors described from time to time in our reports to the Securities and Exchange
Commission (including our Annual Report on Form 10-K). Investors should not consider any list of such factors to be an exhaustive
statement of all of the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making
investment decisions. Shareholders and other readers should not place undue reliance on "forward-looking statements,"
as such statements speak only as of the date of this release.